Many patients with type 2 diabetes are unable to attain and maintain substantial weight loss, despite the clear benefits. Metformin, a biguanide drug, is typically recommended in an individual without risk factors for CVD/CVD/chronic kidney disease (CKD) and/or heart failure (HF) when lifestyle modifications, such as diet and exercise, have not been effective at lowering hyperglycemia. Metformin is first-line therapy for obesity-induced diabetes. Along with reducing blood sugar, metformin causes neither weight gain nor hypoglycemia. Some studies have shown that cardiovascular mortality may be lower in patients prescribed metformin compared with sulfonylureas; however, large cardiovascular outcomes trials have been done with either agent.
Insulin, sulfonylureas, and thiazolidinediones are associated with weight gain.
Learn more about type 2 diabetes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters. Fast Five Quiz: Type 2 Diabetes and Obesity and Weight Management - Medscape - May 16, 2022.